Basf Aktiengesellschaft

Abbott Laboratories Corporation

Hans-Peter Hofmann

Wilfried Lubisch

Gerd Steiner

Laszlo Szabo

Berthold Behl

Francisco Javier Garcia-Ladona

Liliane Unger

Albrecht Franke

Dorothea Starck

Hans-Jurgen Teschendorf

Hans-J&uuml;rgen Teschendorf

Franz Emling

Monika Knopp

Uta Holzenkamp

Kurt Schellhaas

Claus-Dieter Muller

The invention relates to the use of binding partners for 5-HT5-receptors in the treatment of neuropathological and in particular neurodegenerative and/or neuropsychiatric disturbances which can occur notably in cases of cerebral ishcemia, cerebral stroke, epilepsy and attacks in general, chronic schizophrenia, other psychotic illnesses, dementia, notably Alzheimer's disease, demyelination diseases, notably multiple sclerosis and brain tumors. The invention also relates to methods, especially screening methods, for identifying and characterizing such binding partners.

Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances

Pyrrolyl tetrahydroquinoxalin diones, their production and use in the treatment of diseases

Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia

Pyrrolylquinoxalinediones of the formula I

Pyrrolyl quinoxalindiones their production and use as AMPA receptor antagonists

Heterocyclically substituted nitriles of the formula I ##STR1## where X is SO.sub.2, CO, S, SO or CH.sub.2, A is an alkylene or alkenylene radical of not more than 6 carbon atoms, B is --CH.dbd.CH-- or S, and R.sup.1 and R.sup.2 are each hydrogen, halogen, C.sub.1 -C.sub.3 -alkyl, C.sub.1 -C.sub.3 -alkoxy, nitro or trifluoromethyl, and their preparation and use. The novel substances are useful for treating disorders.

Phthalimides and thienopyrrols as drugs

Growing community of inventors

Limburgerhof, Germany

Hans-Peter Hofmann